公开(公告)号：US20240358724A1

公开(公告)日：2024-10-31

申请号：US18648246

申请日：2024-04-26

申请人： North Star Brands, LLC

发明人： Simon Cashmore ,  David Gonzalez-Cameron

IPC分类号： A61K31/00 ,  A23L2/395 ,  A23L2/54 ,  A23L2/60 ,  A61K9/00 ,  A61K47/26 ,  A61K47/32 ,  A61K47/36

CPC分类号： A61K31/658 ,  A23L2/395 ,  A23L2/54 ,  A23L2/60 ,  A61K9/0095 ,  A61K47/26 ,  A61K47/32 ,  A61K47/36

摘要： Disclosed is a beverage tablet that includes a sugar alcohol, a superdisintegrant, a binder having a solubility in 21° C. water that is less than the solubility of D-mannitol, and an active agent (e.g., THC), the tablet having a hardness of at least 1.5 kP and disintegrating in less than 10 minutes when tested according to the Water Disintegration Test Method, and a method of using the beverage tablet.

公开(公告)号：US20240350636A1

公开(公告)日：2024-10-24

申请号：US18757097

申请日：2024-06-27

申请人： AIM Targeted Therapies, Inc.

发明人： Glenn ABRAHMSOHN

IPC分类号： A61K47/02 ,  A61K8/19 ,  A61K8/20 ,  A61K8/22 ,  A61K8/40 ,  A61K8/43 ,  A61K8/46 ,  A61K8/49 ,  A61K8/86 ,  A61K9/00 ,  A61K9/06 ,  A61K31/155 ,  A61K31/18 ,  A61K33/40 ,  A61K47/16 ,  A61K47/26 ,  A61K47/32 ,  A61K47/42 ,  A61L15/18 ,  A61L15/20 ,  A61L15/44 ,  A61L29/08 ,  A61L29/10 ,  A61L29/16 ,  A61L31/08 ,  A61L31/16 ,  A61Q11/00 ,  A61Q17/00

CPC分类号： A61K47/02 ,  A61K8/19 ,  A61K8/20 ,  A61K8/22 ,  A61K8/40 ,  A61K8/43 ,  A61K8/466 ,  A61K8/498 ,  A61K8/86 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/06 ,  A61K31/155 ,  A61K31/18 ,  A61K33/40 ,  A61K47/16 ,  A61K47/26 ,  A61K47/32 ,  A61K47/42 ,  A61L15/18 ,  A61L15/20 ,  A61L15/44 ,  A61L29/08 ,  A61L29/106 ,  A61L29/16 ,  A61L31/08 ,  A61L31/088 ,  A61L31/16 ,  A61Q11/00 ,  A61Q17/005 ,  A61L2300/202 ,  A61L2300/206 ,  A61L2300/404 ,  A61L2300/606 ,  A61L2420/00

摘要： Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided.

公开(公告)号：US12121536B2

公开(公告)日：2024-10-22

申请号：US17646805

申请日：2022-01-03

申请人： Galleon Labs LLC

发明人： Gary S. Hahn ,  Siva Gudi

IPC分类号： A61K33/00 ,  A61K9/00 ,  A61K31/19 ,  A61K31/198 ,  A61K31/22 ,  A61K33/14 ,  A61K47/32 ,  A61K47/54 ,  A61K31/455 ,  A61K33/18 ,  A61K33/38 ,  A61K45/06

CPC分类号： A61K33/00 ,  A61K9/0014 ,  A61K31/19 ,  A61K31/198 ,  A61K31/22 ,  A61K33/14 ,  A61K47/32 ,  A61K47/542 ,  A61K9/0053 ,  A61K31/455 ,  A61K33/18 ,  A61K33/38 ,  A61K45/06 ,  A61K33/14 ,  A61K2300/00 ,  A61K31/22 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00

摘要： Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.

公开(公告)号：US20240325415A1

公开(公告)日：2024-10-03

申请号：US18580005

申请日：2022-07-21

申请人： Nicoventures Trading Limited

发明人： Steven L ALDERMAN ,  Thomas POOLE ,  Karen TALUSKIE ,  Kathryn L WILBERDING ,  Jenni HAWKE ,  Ashley DAVIES ,  Michael S DANIEL ,  Kai TANG ,  Keyi XU ,  Karina MCQUILLAN ,  John CARAWAY

IPC分类号： A61K31/00 ,  A61K9/00 ,  A61K45/06 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38 ,  A61K47/40

CPC分类号： A61K31/658 ,  A61K9/006 ,  A61K36/3482 ,  A61K45/06 ,  A61K47/14 ,  A61K47/32 ,  A61K47/38 ,  A61K47/40

摘要： The present invention relates to compositions comprising active agents formulated for both buccal and gastric delivery wherein the composition also comprises one or more constituent, derivative or extract of cannabis and a further physiologically active agent.

公开(公告)号：US20240315958A1

公开(公告)日：2024-09-26

申请号：US18460441

申请日：2023-09-01

申请人： Chemo Research, S.L.

发明人： Enrico COLLI ,  Carlos DÍEZ FUERTES

IPC分类号： A61K9/00 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

CPC分类号： A61K9/0039 ,  A61K31/565 ,  A61K31/57 ,  A61K47/32 ,  A61K47/34

摘要： The present invention relates to a method for providing contraception in a female subject, comprising continuous intravaginal administration of levonorgestrel of from about 60 μg/day to about 100 μg/day. The invention further relates to a method for treating endometriosis, endometriosis associated pelvic pain (EAPP) and/or dysmenorrhea comprising continuously administering about 60 μg/day to about 160 μg/day of levonorgestrel. Delivery devices, such as, intravaginal rings for putting the methods in practice are also envisaged.

公开(公告)号：US12097245B2

公开(公告)日：2024-09-24

申请号：US17282831

申请日：2020-05-06

申请人： Jing Zhang

发明人： Jing Zhang ,  Wenbo Jin

IPC分类号： A61K38/26 ,  A61K9/00 ,  A61K47/12 ,  A61K47/20 ,  A61K47/32 ,  A61K47/36 ,  A61P3/10

CPC分类号： A61K38/26 ,  A61K9/0053 ,  A61K47/12 ,  A61K47/20 ,  A61K47/32 ,  A61K47/36 ,  A61P3/10

摘要： A pharmaceutical composition having a hypoglycemic effect, comprising: a GLP-1 receptor agonist, and a composition for promoting small-intestinal absorption; wherein the composition for promoting small-intestinal absorption comprises sodium lauryl sulfate, carbomer, chitosan, and sodium citrate. The composition for promoting small intestinal absorption according to the present invention may be prepared into a composite adjuvant, which, when combined with a GLP-1 agonist, can improve the absorption of this active ingredient in the small intestine and the like.

公开(公告)号：US20240307388A1

公开(公告)日：2024-09-19

申请号：US18501268

申请日：2023-11-03

申请人： LIPIDIO PHARMACEUTICALS, INC.

发明人： Nigel R.A Beeley ,  John Gordon Foulkes ,  Kieran George Mooney ,  Charles Rodney Greenaway Evans ,  Keith Arthur Johnson ,  Howard G. Welgus ,  Celia P. Jenkinson ,  James R. Hauske

IPC分类号： A61K31/501 ,  A61K9/00 ,  A61K9/06 ,  A61K31/40 ,  A61K31/4439 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/18 ,  A61K47/32

CPC分类号： A61K31/501 ,  A61K31/40 ,  A61K31/4439 ,  A61K47/02 ,  A61K47/10 ,  A61K47/14 ,  A61K47/183 ,  A61K47/32 ,  A61K9/0014 ,  A61K9/06 ,  A61K45/06

摘要： Pharmaceutical carriers which provide an environment of physical and chemical stability comprising a therapeutically effective amount of an active pharmaceutical ingredient (API) compound of structure I, one or more antioxidants, one or more chelators and a vehicle base comprising water and one or more pharmaceutically acceptable non-aqueous solvents, one or more absorption enhancers, one or more gelling agents and one or more pH buffering agents are described.

公开(公告)号：US20240307300A1

公开(公告)日：2024-09-19

申请号：US18681812

申请日：2021-10-07

申请人： SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED

发明人： Arindam HALDER ,  Ajay Jaysingh KHOPADE

IPC分类号： A61K9/00 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/32 ,  A61K47/34 ,  A61K47/44

CPC分类号： A61K9/0048 ,  A61K31/573 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/183 ,  A61K47/186 ,  A61K47/32 ,  A61K47/34 ,  A61K47/44

摘要： The present invention relates an improved process for the preparation of an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof. The present invention further relates to an aqueous ophthalmic solution of difluprednate or pharmaceutically acceptable salts thereof, prepared by the improved process of the present invention.

公开(公告)号：US20240299434A1

公开(公告)日：2024-09-12

申请号：US18547777

申请日：2022-01-27

申请人： PHARMA CINQ. LLC

发明人： Michael Kevin BAMAT ,  Yi GAO ,  Jeffrey A. MILLER ,  Yihong QIU

IPC分类号： A61K31/7072 ,  A61K47/32 ,  A61K47/38

CPC分类号： A61K31/7072 ,  A61K47/32 ,  A61K47/38

摘要： There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability.

公开(公告)号：US20240299419A1

公开(公告)日：2024-09-12

申请号：US18667326

申请日：2024-05-17

申请人： scPharmaceuticals Inc.

发明人： Alfredo Grossi ,  Britt Kostraba ,  Olatokumbo Olajimi Luca Ogunleye ,  Shannon Terry ,  Franciscus Koppenhagen

IPC分类号： A61K31/635 ,  A61K47/10 ,  A61K47/18 ,  A61K47/32 ,  A61M5/142

CPC分类号： A61K31/635 ,  A61K47/10 ,  A61K47/18 ,  A61K47/32 ,  A61M5/14248

摘要： Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.